Navigation Links
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
Date:12/13/2008

HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ -- Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.

HER2+ patients are commonly identified as high risk, yet MammaPrint was able to identify a low risk subgroup of HER2+ patients, who subsequently experienced a 10 year disease-free survival of close to 90 percent even in the absence of (neo)adjuvant trastuzumab (Herceptin(R)) and chemotherapy. Additionally, in a subgroup of highly endocrine responsive HER2/NEU positive patients, MammaPrint(R) low risk patients had no relapse.

The results were presented by Dr. Michael Knauer during the 2008 San Antonio Breast Cancer Symposium (SABCS). In the study population of 169 HER2+ patients MammaPrint(R) classified 16 percent of patients as having a good prognosis signature with a 10-year distant disease-free survival (DDFS) of 89 percent, compared to 84 percent of patients classified as having a poor prognosis signature with a DDFS of 64 percent.

MammaPrint(R)'s robustness is underscored by the 70 gene panel unique to the test and a resulting gene profile that covers all molecular pathways associated with breast cancer. HER2/NEU-overexpression is observed in 15-20 percent of invasive breast cancers and is widely considered to be a negative prognostic factor. As a result, current treatment guidelines classify all HER2-positive breast cancer patients at high risk of relapse, and recommend trastuzumab and chemotherapy.

MammaPrint(R) accurately identified a subgroup of patients with a good clinical outcome in HER2+ early breast cancer. These patients will be further studied in the ongoing MINDACT-trial (Microarra
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
5. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
6. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
7. New Breast Imaging Technology Targets Hard-to-Detect Cancers
8. New Mammography Technology Effective in Detecting Breast Cancer
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... Pharmaceuticals, Inc., (NASDAQ: ACRX ) ("AcelRx"), a ... of innovative therapies for the treatment of acute and ... patent granted by the European Patent Office expired on ... that the patent has been opposed. The patent (European ...
... China, May 9, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... announced today that the Company filed its annual report ... 2010 with the Securities and Exchange Commission on May ...
Cached Medicine Technology:AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period 2AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... During the Western United States’ worst ever ... low, Southern Oregon’s water is proving resistant to drought ... mountain snow pack on record in 2014, remain high ... That was the observation of journalist-hikers Art Bernstein and ... Oregon,” during an interview with water advocate Sharon Kleyne.† ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... there are only 24 hours in a day, that doesn’t seem ... time within their busy schedules for exercise and fitness. Fortunately, one ... get in shape. Here are five ways you can reach your ... Up Your Commute , Consider riding a bike or taking the ... daily routine. If you must use your car to get to ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... Medical Center found that antiviral therapy during compensated cirrhosis, ... cost-effective approach to treating patients with advanced liver disease ... in the June issue of Liver Transplantation , ... American Association for the Study of Liver Diseases (AASLD). ...
... in study remained uninfected, but ,safe sex, still urged, experts ... are HIV-positive can lower their risk for transmitting the virus ... new research has found. , Antiretroviral drug therapy helps ... turn makes the person less infectious to others. The drugs ...
... , ... and technology solutions you can trust, proudly announces the opening of a new technology solutions ... new location, they are offering 10% off all business IT and Phoenix computer repair services ... ...
... Axendia Launches ... ... products has created unique and demanding challenges for the Life Sciences industry and the U.S. ... are preparing to take significant steps to secure the Global Supply Chain. Axendia, Inc., ...
... ... ... Nash, the Connecticut woman who made headlines after a friend,s chimpanzee brutally attacked her was ... 200-pound chimp left Nash horrifically disfigured, without her nose, lips, hands, and eyesight. After the ...
... ... and Effectiveness. , ... Charlottesville, VA, San Francisco, CA, New York, NY and Paris, France (PRWEB) May 27, ... managing Investigator Initiated Studies/ Trials (IIS/IIT). openIIS 2.5 provides a broad set of ...
Cached Medicine News:Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2Health News:Anti-HIV Drugs May Help Prevent Spread of Virus 2Health News:my PC Techs Opens New Technology Solutions Office in Ahwatukee 2Health News:“Global Supply Chain Visibility and Security; Business Necessity, Regulatory Imperative” 2Health News:Complicated Surgeries Carry Greater Risks, Possible Need for New York Medical Malpractice Attorneys According To David Perecman 2Health News:Complicated Surgeries Carry Greater Risks, Possible Need for New York Medical Malpractice Attorneys According To David Perecman 3Health News:OpenQ Announces the Release of openIIS 2.5 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: